| Objective To explore the efficacy of voriconazole and caspofungin in the treatment of invasive lung infection complicated by liver failure.Methods A total of 78 patients with ACLF complicated with IPA who were treated with voriconazole and caspofungin in our hospital from January 2016 to June 2020 were collected as the research subjects.A total of 29 patients treated with voriconazole were included in the voriconazole group,and 49 patients treated with caspofungin were included in the caspofungin group.The changes of liver function indexes and serum inflammatory factors,treatment effects,outcomes and adverse drug reactions were compared between the two groups before and after treatment.Results After treatment,the INR of the voriconazole group was (1.39±0.13),which was lower than that of the caspofungin group (1.48±0.05),and the difference between the two groups was statistically significant (P<0.05).After treatment,the levels of white blood cell (WBC),proealcitonin (PCT) and C-reactive protein (CRP) were (10.58±1.82) ×109/L,(1.49±0.41) ng/dL,and (34.88±6.44) mg/L in the voriconazole group,which were compared with (9.74±1.11)×109/L,(1.31±0.33) ng/dL,(35.33±6.37) mg/L in the caspofungin group,and no differences were statistically significant(P>0.05).The improvement rate,and the survival rates after 4 weeks and 6 months follow-up were 89.66%,68.97% and 58.62%respectively in the voriconazole group,and no statistical significances were observed when those were compared with 85.71%,67.35% and 57.14% in the caspofungin group (P>0.05).Conclusion Both voriconazole and caspofungin show good efficacy in the treatment of ACLF complicated with IPA,without obvious side effects. |
